4523 On Other Exchanges
Symbol
Exchange
4523 is not on other exchanges.

Executive Profile*

Gary Hendler

Senior Vice President, Chief Commercial Officer of Oncology Business Group, President of EMEA Region, President of Eisai Global Oncology Business Unit, Chairman of Eisai Europe Ltd, Chief Executive Officer of Eisai Europe Ltd and President of Eisai Europe Ltd ,Eisai Co., Ltd.
AgeTotal Calculated CompensationThis person is connected to 13 board members in 1 different organizations across 1 different industries.

See Board Relationships
50¥149,000,000
As of Fiscal Year 2016

Background*

Gary Hendler serves as Senior Vice President at Eisai Co., Ltd. and serves as its Chief Commercial Officer of Oncology Business Group. Gary Hendler serves as Chief Executive Officer of Eisai Europe Ltd, President of Eisai Europe Ltd, President of Emea Region and President of Eisai Global Oncology Business Unit. Gary Hendler served as Vice President of Eisai Co. Ltd. since June 18, 2010 and serves as its President of EMEA Region. Gary Hendler serves as Chief Executive ...

Read Full Background

Corporate Headquarters*

4-6-10, Koishikawa
Tokyo, -- 112-8088

Japan

Phone: 81 3 3817 3016
Fax: 81 3 3811 6032

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

There is no Education data available.

Other Affiliations*

There is no Company Affiliations data available.

Annual Compensation*

Salary¥77,000,000
Bonus¥53,000,000
Total Annual Compensation¥130,000,000

Stock Options*

Long Term Incentive Plan¥19,000,000

Total Compensation*

Total Annual Cash Compensation¥130,000,000
Total Short Term Compensation¥130,000,000
Total Calculated Compensation¥149,000,000
*Data is at least as current as the most recent Definitive Proxy.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President, Director and Member of Stock Option Committee
Innoviva, Inc.
$721.4K
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$892.6K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
Peter S. Greenleaf Chairman and Chief Executive Officer
Sucampo Pharmaceuticals, Inc.
$565.3K
Eduardo Javier Sanchiz Yrazu Chief Executive Officer, Member of Management Board, Executive Director and Member of Compliance Committee
Almirall, S.A.
€1.1M
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EISAI CO LTD, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.